IDH1/2突变作为急性髓系白血病可测量残留病检测生物标志物的效用
该研究在163例新诊断IDH突变急性髓系白血病患者中,采用基于二代测序的方法检测强化化疗完全缓解后持续存在的IDH1/2突变,并通过独立超滚环扩增试验验证高灵敏度(10⁻⁴)。结果显示持续IDH2突变患者复发风险显著增加(P=.027;SHR,2.34),而持续IDH1突变无显著关联(P=.591;SHR,0.80)。
要点
- 持续IDH2突变与复发风险显著增加相关(P=.027;SHR,2.34)。
- 持续IDH1突变与复发风险无显著关联(P=.591;SHR,0.80)。
- 无伴发NPM1突变或FLT3-ITD的IDH2突变患者中,持续IDH2与复发关联最显著(P=.011;SHR,5.29)。
核心结论
- 突变型IDH2似乎是一种潜在有用的新分子MRD标志物,在急性髓系白血病中具有预后意义。
研究设计与样本
- 研究纳入163例新诊断IDH突变急性髓系白血病患者,患者入组荷兰-比利时血液肿瘤合作试验组和瑞士临床癌症研究组的临床试验。
- 采用基于二代测序的方法靶向IDH1(R132)和IDH2(R140和R172)所有热点突变,检测强化化疗完全缓解后持续存在的IDH1/2突变。
- 采用独立的超滚环扩增试验确认基于二代测序方法检测的高灵敏度(10⁻⁴)及持续IDH1/2突变水平。
主要发现
- 持续IDH2突变可测量患者的复发风险显著增加(P=.027;亚分布风险比(SHR),2.34)。
- 持续IDH1突变患者的复发风险无显著增加(P=.591;SHR,0.80)。
- 持续IDH2突变与复发风险增加的关联在无伴发NPM1突变或FLT3-ITD的IDH2突变急性髓系白血病患者中最为显著(P=.011;SHR,5.29)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular measurable residual disease (MRD) assessment in patients with acute myeloid leukemia (AML) has been established for only a few specific markers: mutant NPM1 and FLT3 internal tandem duplication (ITD). Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are present in ∼20% of patients with AML. However, validation of mutant IDH1/2 MRD has been hampered by cohort size as well as the availability of highly sensitive and specific MRD detection assays. Here, we comprehensively investigate the impact of persistent IDH1/2 mutations in complete remission after intensive chemotherapy in a cohort of 163 newly diagnosed patients with IDH-mutant AML, enrolled in Dutch-Belgian Cooperative Trial Group for Hematology-Oncology and Swiss Group for Clinical Cancer Research clinical trials, using a next-generation sequencing (NGS)-based approach, targeting all hot spot mutations in IDH1 (R132) and IDH2 (R140 and R172). The high sensitivity (10-4) as well as the levels of persistent IDH1/2 mutations detected by the NGS-based approach were confirmed by an independent super rolling circle amplification assay. We demonstrate that the risk of relapse was significantly increased in patients with AML with measurable persistent IDH2 mutations (P = .027; subdistribution hazard ratio (SHR), 2.34) but not in patients with persistent mutant IDH1 (P = .591; SHR, 0.80). Moreover, the association of persistence of mutant IDH2 and increased risk of relapse was most pronounced in patients with mutant IDH2 AML without concomitant NPM1 mutations or FLT3-ITD (P = .011; SHR, 5.29). Thus, mutant IDH2 appears as a potentially useful novel molecular MRD marker with prognostic significance in AML.
引用
- Boertjes EL, Vonk CM, Kavelaars FG, et al. Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia. Blood Adv. 2025. PMID: 40674738. doi:10.1182/bloodadvances.2025016726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。